Methods: The Telavancin Observational Use Registry (TOUR™) is a multicenter study designed to characterize TLV prescribing patterns in clinical practice. Data are obtained from medical charts through standardized case report forms to characterize infection types, pathogens, and outcomes. Efficacy and safety are assessed for up to 30 days after TLV treatment and clinical success is based on the investigator’s assessment of the medical chart. The TOUR study will obtain data from 50–60 US hospitals and outpatient infusion centers. Patients who received at least 1 dose of TLV are eligible for inclusion. Descriptive analyses will be performed to assess patient demographics, clinical outcomes, and renal adverse events. Results will be stratified by infection type.
Results: At the cutoff date of April 28, 2016, data for 200 patients had been collected from 25 sites. Of these patients, 25% were ≥65 years (median age 55, range 15–92), 54% were male, and 84% were white. The primary infections in these patients included complicated skin and skin structure infection (44%); bone and joint infections (30%); bacteremia (13%); pneumonia (6%); and other types (7%). The predominant pathogens were MRSA (51%), MSSA (15%), and coagulase negative staphylococci (10%). The median TLV dose and duration of treatment were 750 mg (range 100–2000 mg) and 16 days (range 1−299 days), respectively. Positive clinical response (cured or improved to step-down oral therapy) was observed in 74% of patients while 9% of patients failed treatment and 17% were non-evaluable.
Conclusion: The TOUR study has identified TLV usage in bone and joint infections and bacteremia in addition to labeled indications. This study will continue to enroll patients, and will further characterize patterns of TLV usage in the real world, including both inpatient and outpatient settings.
Theravance Biopharma US Inc.:
C. Lucasti, Theravance Biopharma U.S., Inc.: Investigator , Research grant
L. Saravolatz, Theravance Biopharma US Inc.: Grant Investigator and Speaker's Bureau , Grant recipient and Speaker honorarium
TAXIS: Research Contractor , Research grant
D. Besece, Theravance Biopharma Inc.: Employee and Shareholder , Salary
C. Sherman, Theravance Biopharma Inc.: Employee and Shareholder , Salary
B. Castaneda-Ruiz, Theravance Biopharma Inc.: Employee and Shareholder , Salary
See more of: Poster Abstract Session